# De novo Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/de-novo-biotherapeutics

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.denovobio.co.kr
- Total disclosed funding: $7.1M
- Latest round: Series A (Nov 25, 2022)
- Investors on record: 4

## About

Based in Seoul, South Korea, and founded in 2021, D De novo Biotherapeutics, Inc. a.k.a. De novo Biotherapeutics is a biotechnology firm that focuses on developing mRNA (messenger ribonucleic acid) encoded and NK (natural killer) cell-engaging bi- or multi-specific antibodies for the treatment, diagnosis, and prevention of cancer. In November 2022, De novo Biotherapeutics raised KRW 7.8 billion in a Series A funding from Stonebridge Ventures, Heungkuk Securities, DS & Partners, and Atinum Investment. As of November 2022, Changhoon Choi is the CEO of the company.

The company develops multi-specific antibodies through mRNA technology to harness the anti-tumor activity of patients’ NK cells. The product pipeline of De novo Biotherapeutics includes DNB -101, DNB -102, and DNB -103, targeting cancer diseases.  

De novo Biotherapeutics plans to use its proceeds from November 2022 funding to develop a new drug that attracts NK cells to mRNA.

## Funding rounds

- Series A, Nov 25, 2022, $5.8M — Atinum Investment, Heungkuk Securities, DS & Partners, Stonebridge Ventures
- Seed, Oct 20, 2021, $1.2M — Atinum Investment, DS & Partners

## Investors

- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Seed, Series A
- DS & Partners (https://capitalatlas.ai/funds/ds-partners) — Seed, Series A
- Heungkuk Securities — Series A
- Stonebridge Ventures — Series A